24th Oct 2023 07:00
Renalytix plc
("Renalytix" or the "Company")
Directorate change
LONDON and SALT LAKE CITY - October 24, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that Timothy Scannell has stepped down from his role as independent Non-Executive Director of Renalytix effective as of October 18, 2023, to pursue other opportunities.
James McCullough, CEO of Renalytix plc, commented: "It has been a wonderful learning experience to work alongside Tim for the past 18 months. He has been a significant contributor to Renalytix, and I would like to thank him for all his efforts on the Board."
For further information, please contact:
Renalytix plc | www.renalytix.com |
James McCullough, CEO | Via Walbrook PR |
| |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
| |
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
Gary Clarence / Shalin Bhamra |
|
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 |
CapComm Partners | |
Peter DeNardo | Tel: 415-389-6400 or [email protected] |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis? for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
Related Shares:
Renalytix Plc